Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study.
albuminuria
chronic kidney disease
finerenone
kidney outcomes
type 2 diabetes
Journal
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
ISSN: 1460-2385
Titre abrégé: Nephrol Dial Transplant
Pays: England
ID NLM: 8706402
Informations de publication
Date de publication:
13 02 2023
13 02 2023
Historique:
received:
20
10
2021
pubmed:
23
4
2022
medline:
15
2
2023
entrez:
22
4
2022
Statut:
ppublish
Résumé
In FIGARO-DKD, finerenone reduced the risk of cardiovascular events in patients with type 2 diabetes (T2D) and stage 1-4 chronic kidney disease (CKD). In FIDELIO-DKD, finerenone improved kidney and cardiovascular outcomes in patients with advanced CKD. This analysis further explores kidney outcomes in FIGARO-DKD. FIGARO-DKD (NCT02545049) included patients with urine albumin-to-creatinine ratio (UACR) 30-<300 mg/g and estimated glomerular filtration rate (eGFR) 25-90 mL/min/1.73 m2 or UACR 300-5000 mg/g and eGFR ≥60 mL/min/1.73 m2. Outcomes included two composite kidney endpoints, a composite of ≥40% decrease in eGFR from baseline sustained over ≥4 weeks, kidney failure or renal death, and a composite of ≥57% decrease in eGFR from baseline sustained over ≥4 weeks, kidney failure or renal death. Changes in albuminuria and eGFR slope were also analyzed. Kidney and CV outcomes were evaluated by baseline UACR. A lower incidence rate for the eGFR ≥40% kidney composite endpoint was observed with finerenone compared with placebo, but the between-group difference was not significant [hazard ratio (HR) = 0.87; 95% confidence interval (CI): 0.76-1.01; P = .069]. A greater treatment effect was observed on the eGFR ≥57% kidney composite endpoint (HR = 0.77; 95% CI: 0.60-0.99; P = 0.041) with a 36% relative risk reduction for end-stage kidney disease. A larger magnitude of effect on kidney outcomes was observed with finerenone versus placebo for patients with severely increased albuminuria than with moderately increased albuminuria. Improvements in UACR, eGFR slope and cardiovascular risk were evident in both subgroups with finerenone. The present analyses suggest that finerenone protects against kidney disease progression and cardiovascular events in patients with T2D and early- or late-stage CKD.
Sections du résumé
BACKGROUND
In FIGARO-DKD, finerenone reduced the risk of cardiovascular events in patients with type 2 diabetes (T2D) and stage 1-4 chronic kidney disease (CKD). In FIDELIO-DKD, finerenone improved kidney and cardiovascular outcomes in patients with advanced CKD. This analysis further explores kidney outcomes in FIGARO-DKD.
METHODS
FIGARO-DKD (NCT02545049) included patients with urine albumin-to-creatinine ratio (UACR) 30-<300 mg/g and estimated glomerular filtration rate (eGFR) 25-90 mL/min/1.73 m2 or UACR 300-5000 mg/g and eGFR ≥60 mL/min/1.73 m2. Outcomes included two composite kidney endpoints, a composite of ≥40% decrease in eGFR from baseline sustained over ≥4 weeks, kidney failure or renal death, and a composite of ≥57% decrease in eGFR from baseline sustained over ≥4 weeks, kidney failure or renal death. Changes in albuminuria and eGFR slope were also analyzed. Kidney and CV outcomes were evaluated by baseline UACR.
RESULTS
A lower incidence rate for the eGFR ≥40% kidney composite endpoint was observed with finerenone compared with placebo, but the between-group difference was not significant [hazard ratio (HR) = 0.87; 95% confidence interval (CI): 0.76-1.01; P = .069]. A greater treatment effect was observed on the eGFR ≥57% kidney composite endpoint (HR = 0.77; 95% CI: 0.60-0.99; P = 0.041) with a 36% relative risk reduction for end-stage kidney disease. A larger magnitude of effect on kidney outcomes was observed with finerenone versus placebo for patients with severely increased albuminuria than with moderately increased albuminuria. Improvements in UACR, eGFR slope and cardiovascular risk were evident in both subgroups with finerenone.
CONCLUSIONS
The present analyses suggest that finerenone protects against kidney disease progression and cardiovascular events in patients with T2D and early- or late-stage CKD.
Identifiants
pubmed: 35451488
pii: 6572377
doi: 10.1093/ndt/gfac157
pmc: PMC9923706
doi:
Substances chimiques
finerenone
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
372-383Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the ERA.
Références
Lancet Diabetes Endocrinol. 2019 Feb;7(2):128-139
pubmed: 30635226
Eur Heart J. 2018 May 1;39(17):1535-1542
pubmed: 29554312
PLoS One. 2020 Mar 24;15(3):e0230512
pubmed: 32208435
N Engl J Med. 2020 Dec 03;383(23):2219-2229
pubmed: 33264825
Lancet Diabetes Endocrinol. 2019 Feb;7(2):115-127
pubmed: 30635225
PLoS One. 2019 Feb 27;14(2):e0212184
pubmed: 30811447
Am J Kidney Dis. 2014 Dec;64(6):821-35
pubmed: 25441437
Lancet. 2012 Nov 10;380(9854):1662-73
pubmed: 23013602
Clin J Am Soc Nephrol. 2017 Dec 7;12(12):1941-1949
pubmed: 28893924
J Am Coll Cardiol. 2018 Oct 9;72(15):1845-1855
pubmed: 30075873
Endocr Pract. 2008 Nov;14(8):985-92
pubmed: 19095597
J Am Soc Nephrol. 2013 Feb;24(2):302-8
pubmed: 23362314
BMJ Open. 2016 Oct 7;6(10):e012062
pubmed: 27855091
Eur Heart J. 2013 Aug;34(31):2453-63
pubmed: 23713082
N Engl J Med. 2019 Jun 13;380(24):2295-2306
pubmed: 30990260
Am J Kidney Dis. 2020 Jan;75(1):84-104
pubmed: 31473020
Hypertension. 2015 Feb;65(2):257-63
pubmed: 25368026
J Am Soc Nephrol. 2020 Dec;31(12):2925-2936
pubmed: 32998938
Diabetes Care. 2020 Jan;43(Suppl 1):S135-S151
pubmed: 31862754
J Am Soc Nephrol. 2017 Apr;28(4):1216-1226
pubmed: 28087726
N Engl J Med. 2021 Oct 14;385(16):1451-1461
pubmed: 34449189
N Engl J Med. 2021 Dec 9;385(24):2252-2263
pubmed: 34449181
Clin J Am Soc Nephrol. 2006 Sep;1(5):940-51
pubmed: 17699311
Kidney Int. 2020 Oct;98(4S):S1-S115
pubmed: 32998798
Am J Nephrol. 2019;50(5):345-356
pubmed: 31665733
Eur Heart J. 2021 Jan 7;42(2):152-161
pubmed: 33099609
J Cardiovasc Pharmacol. 2014 Jul;64(1):69-78
pubmed: 24621652
BMJ Open Diabetes Res Care. 2016 Apr 11;4(1):e000154
pubmed: 27110365
Ann Intern Med. 2001 Jul 17;135(2):73-87
pubmed: 11453706